Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
Completed · Phase 3 · NCT03657160
Conditions: Hematopoietic Stem Cells
At a glance
- Research payments reported, 2025
- $22,071
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 343
About the trial
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Tested
- Vedolizumab Placebo (drug), Vedolizumab (drug)
- Dates
- Started 2019-02-06; completion 2022-05-09
- Results posted
- Yes
The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.
From ClinicalTrials.gov, last updated 2023-06-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $22,071 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Omer Jamy Hematology & Oncology · Birmingham, AL
- Yi-bin A. Chen, MD Hematology & Oncology · Boston, MA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of Alabama Hospital, AL $19,516
- Dana-Farber Cancer Institute $2,555
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.